Corrigendum Corrigendum to ‘‘Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2a (HRI) kinase” [Bioorg. Med. Chem. Lett. 19 (2009) 6548] Mark D. Rosen *, Craig R. Woods, Steven D. Goldberg, Michael D. Hack, A. Dawn Bounds, Young Yang, Pamela C. Wagaman, Victor K. Phuong, Angela P. Ameriks, Terrance D. Barrett, Kimon C. Kanelakis, Jui Chang Chuang, Nigel P. Shankley, Michael H. Rabinowitz Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States
A series of indeno[1,2-c]pyrazoles were discovered to be the first known inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase. The synthesis, structure-activity relationship profile, and in-vitro pharmacological characterization of this inaugural series of HRI kinase inhibitors are detailed.
Craig R. Woods合作论文数3Michael D. Hack合作论文数3Mark D. Rosen合作论文数3Kimon C. Kanelakis合作论文数Johnson & Johnson Pharmaceutical Research and Development, L.L.C.3Nigel P. Shankley合作论文数3
Young Yang合作论文数3Michael H. Rabinowitz合作论文数Johnson & Johnson Pharmaceutical Research and Development, L.L.C.3Steven D. Goldberg合作论文数3Pamela C. Wagaman合作论文数3Terrance D. Barrett合作论文数3Victor K. Phuong合作论文数3Jui Chang Chuang合作论文数2Jui Chang合作论文数1
